BMO Capital Markets restated their buy rating on shares of Pfizer, Inc. (NYSE:PFE) in a research note published on Friday morning. The firm currently has a $39.00 target price on the biopharmaceutical company’s stock.
Several other research analysts also recently weighed in on the stock. Credit Suisse Group downgraded shares of Pfizer from an outperform rating to a neutral rating and lowered their price objective for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. Zacks Investment Research upgraded shares of Pfizer from a sell rating to a hold rating in a research note on Friday, July 14th. Vetr lowered shares of Pfizer from a buy rating to a hold rating and set a $35.71 target price for the company. in a research note on Wednesday, September 13th. Morgan Stanley upgraded shares of Pfizer from an equal weight rating to an overweight rating and upped their target price for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Finally, ValuEngine upgraded shares of Pfizer from a hold rating to a buy rating in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. Pfizer has a consensus rating of Hold and a consensus price target of $38.48.
Pfizer (NYSE PFE) opened at $35.24 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 1-year low of $30.51 and a 1-year high of $36.78. The firm has a market cap of $210,220.00, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the prior year, the company posted $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. equities analysts forecast that Pfizer will post 2.59 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/pfizer-inc-pfe-rating-reiterated-by-bmo-capital-markets/1775116.html.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.63%. Pfizer’s dividend payout ratio is presently 78.53%.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders have sold 374,621 shares of company stock valued at $12,796,098 in the last quarter. Company insiders own 0.06% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer in the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer in the second quarter worth about $103,000. D. Scott Neal Inc. lifted its holdings in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer in the first quarter worth about $121,000. 69.36% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with our FREE daily email newsletter.